GSE158438 lenalidomide IRCC-Neuromed-FL 1 v 9 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE158438_lenalidomide_IRCC-Neuromed-FL_1_v_9_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE158438_lenalidomide_IRCC-Neuromed-FL_1_v_9_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE158438_lenalidomide_IRCC-Neuromed-FL_1_v_9_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE158438_lenalidomide_IRCC-Neuromed-FL_1_v_9_human_up.

Results found

Linked to

 

Label

Description

 

Gene

KLRK1 antisense RNA 1

Gene

HOXB cluster antisense RNA 4

Gene

T cell receptor gamma variable 7 (pseudogene)

Gene

ribosomal protein L7a pseudogene 19

Gene

ribosomal protein S2 pseudogene 36

Gene

RNA, variant U1 small nuclear 6

Gene

microRNA 4319

Gene

diacylglycerol kinase theta

Gene

lysophosphatidic acid receptor 5

Gene

ring finger protein 166

  • Gene

    KLRK1 antisense RNA 1


  • Gene

    HOXB cluster antisense RNA 4


  • Gene

    T cell receptor gamma variable 7 (pseudogene)


  • Gene

    ribosomal protein L7a pseudogene 19


  • Gene

    ribosomal protein S2 pseudogene 36


  • Gene

    RNA, variant U1 small nuclear 6



  • Gene

    diacylglycerol kinase theta


  • Gene

    lysophosphatidic acid receptor 5


  • Gene

    ring finger protein 166

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.